A5052155368- Autoimmune Bullous Skin Diseases
- Urticaria and Related Conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Inflammatory Myopathies and Dermatomyositis
- Systemic Sclerosis and Related Diseases
- Immunodeficiency and Autoimmune Disorders
- Drug-Induced Adverse Reactions
- Muscle and Compartmental Disorders
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Food Allergy and Anaphylaxis Research
- Infective Endocarditis Diagnosis and Management
- Renal Diseases and Glomerulopathies
- Contact Dermatitis and Allergies
- Infectious Aortic and Vascular Conditions
- Patient-Provider Communication in Healthcare
- Healthcare Systems and Technology
- Antifungal resistance and susceptibility
- Vasculitis and related conditions
- Social Media in Health Education
- Allergic Rhinitis and Sensitization
- Nail Diseases and Treatments
- Tracheal and airway disorders
- Blood disorders and treatments
- Cystic Fibrosis Research Advances
- Fungal Infections and Studies
Pathwest Laboratory Medicine
2018-2025
Fiona Stanley Hospital
2019-2025
Sir Charles Gairdner Hospital
2018-2019
Royal Perth Hospital
2018-2019
Queen Elizabeth II Medical Centre
2018-2019
The epidemiology, clinical characteristics and outcomes of antimicrobial-associated anaphylaxis remain ill-defined. We sought to examine antimicrobial with regard to: (i) the frequency implicated antimicrobials; (ii) attributable mortality; (iii) referral for definitive allergy assessment.This was conducted through a national retrospective multicentre cohort study at five Australian tertiary hospitals (January 2010 December 2015). Cases were identified from ICD-10 coding adverse drug...
Abstract There is a lack of real‐world data on the use omalizumab in treatment‐refractory chronic spontaneous urticaria (CSU). A single‐centre retrospective cohort study was performed to assess efficacy and safety for CSU. The overall response rate 67% comparable with that reported literature. Disease control sustained remission can be achieved omalizumab, even patients treatment‐resistant
Background: Mutations in the TMEM 173 gene underlie a type I interferon associated disease, STING vasculopathy with onset infancy (SAVI).Patients suffer cutaneous and interstitial lung but are not known to life-threatening infection.Case: We describe child who presented Pneumocystis jirovecii pneumonia early life, from which he recovered.He went on failure thrive, developmental delay, livido reticularis vesicular rash, without vasculitis, normal C-reactive protein erythrocyte sedimentation...